An ultra-high-density protein microarray for high throughput single-tier serological detection of Lyme disease
| Autor: | Vasanth Jayaraman, Yuzheng Ou, Hari Krishnan Krishnamurthy, Yuanyuan Yang, Kang Bei, Karthik Krishna, Karenah J Rajasekaran, John J. Rajasekaran, Tianhao Wang, Alex J. Rai, Daniel Green |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microarray 030106 microbiology Protein Array Analysis lcsh:Medicine Article Serology Cohort Studies 03 medical and health sciences Lyme disease Bacterial Proteins medicine Humans Serologic Tests Borrelia burgdorferi lcsh:Science Lyme Disease Multidisciplinary Lab-on-a-chip medicine.diagnostic_test biology Assay systems business.industry lcsh:R medicine.disease biology.organism_classification High-Throughput Screening Assays LYME 030104 developmental biology Case-Control Studies Immunoassay Immunology Protein microarray Lyme disease microbiology lcsh:Q Bacterial infection business Microbiology techniques Algorithms Biomarkers |
| Zdroj: | Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020) Scientific Reports |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-020-75036-2 |
| Popis: | Current serological immunoassays have inherent limitations for certain infectious diseases such as Lyme disease, a bacterial infection caused by Borrelia burgdorferi in North America. Here we report a novel method of manufacturing high-density multiplexed protein microarrays with the capacity to detect low levels of antibodies accurately from small blood volumes in a fully automated system. A panel of multiple serological markers for Lyme disease are measured using a protein microarray system, Lyme Immunochip, in a single step but interpreted adhering to the standard two-tiered testing algorithm (enzyme immunoassay followed by Western blot). Furthermore, an enhanced IgM assay was supplemented to improve the test’s detection sensitivity for early Lyme disease. With a training cohort (n = 40) and a blinded validation cohort (n = 90) acquired from CDC, the Lyme Immunochip identified a higher proportion of Lyme disease patients than the two-tiered testing (82.4% vs 70.6% in the training set, 66.7% vs 60.0% in the validation set, respectively). Additionally, the Immunochip improved sensitivity to 100% while having a lower specificity of 95.2% using a set of investigational antigens which are being further evaluated with a large cohort of blinded samples from the CDC and Columbia University. This universal microarray platform provides an unprecedented opportunity to resolve a broad range of issues with diagnostic tests, including multiplexing, workflow simplicity, and reduced turnaround time and cost. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|